Izotropic’s AI Breakthrough Positions IzoView to Redefine Breast CT Imaging Standards - Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT -
BreastCT.com Debuts as Go-To Resource for Breast CT Technology & Izotropic’s IzoView DeviceVANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of BreastCT.com, a new online platform supporting the Company’s awareness initiatives.
Izotropic’s IzoView Positioned to Capitalize on Key Global Breast Imaging Market Drivers- Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand
Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast ImagingVANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic”, or the “Company”), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of its new podcast series. The first episode Beyond the Mammogram: Rethinking the Future of Breast Imaging is now available in English, Arabic, Chinese, French, German, Italian and Spanish.
Izotropic’s IzoView Breast CT Device Stands Distinct vs Existing Breast Imaging Technologies- IzoView positioned to disrupt high-growth breast imaging markets with target device price of USD $500K
